Maverique
An autonomous gender that is completely separate from male and female.
Maverique is a term coined in 2014 by Vesper H. to describe a gender identity that is experienced as completely autonomous and independent of masculinity or femininity. It is not a neutral space between male and female, but a distinct gender.
Maverique differs from neutrois and agender in that it describes a positive, independent identity. The term was deliberately chosen to distance itself from terms like non-binary, which define the identity as something it is not.
Critical Analysis
Maverique is one of many identities conceived online and spread via social media. The speed with which new identities emerge raises questions about their stability over time—and about who has the authority to define new genders.
Related identities:
Related topics:
Origin and spread
The Maverique identity emerged in online subcultures on Tumblr, Reddit, and TikTok in the 2010s. Its growth did not stem from clinical research or anthropological description, but rather from self-identification and peer validation. What begins as a personal experience rapidly becomes an established category within those circles, complete with its own flag, pronouns, and strict definitions.
The spread occurs almost entirely through social media and youth culture. That is no minor detail. ROGD (Rapid Onset Gender Dysphoria) research suggests that social clustering—groups of friends in which multiple young people simultaneously develop a new identity—is a significant explanatory factor. The gender-affirmative sector ignores this signal or dismisses it as transphobic, while parents and clinicians do observe it in practice.
Test against clinical evidence
An identity label only becomes medically relevant when it leads to interventions: social transition, puberty blockers, cross-sex hormones, surgeries. It is precisely at this point that the house of cards that is the evidence base collapses. The Cass Review (2024) describes the evidence base for puberty blockers and hormones in minors as weak. NICE (2020) classified all relevant studies as having very low certainty.
Sweden (SBU, 2022) and Finland (COHERE, 2020) reverted their protocols to a “psychotherapy-first” approach. Norway (UKOM, 2023) described the care as experimental. NHS England ceased routine prescribing of puberty blockers. The WPATH Files (2024) revealed that even WPATH clinicians were debating among themselves about informed consent and irreversible side effects.
Why this resistance matters
The proliferation of identity labels such as Maverique is not an innocent linguistic innovation. It serves as a gateway to medical treatment for young people struggling with ordinary adolescent uncertainty. Detransitioners—people who reverse their transition—describe how, in their search for themselves, they were affirmed at every step toward medicalization, and rarely encountered anyone who put the brakes on.
Resistance to this dynamic often comes from mothers, lesbian women, pediatricians, and psychiatrists who see what is happening and break their silence despite the career risks. Their voices should no longer be dismissed as hate—they describe a reality that the gender-affirmative model refuses to see.
International Reconsideration
In recent years, several national health authorities have distanced themselves from the gender-affirming model for minors. The common denominator: the evidence for lasting benefits is lacking, while the risks are real.
Cass Review (2024). Review commissioned by NHS England, conducted by Hilary Cass. Conclusion: the evidence base for puberty blockers and cross-sex hormones in minors is weak. NHS England ceased routine prescribing of puberty blockers outside of clinical trials.
SBU — Sweden (2022). The Swedish Agency for Health Technology Assessment (SBU) and Karolinska University Hospital discontinued the use of puberty blockers and hormones for minors outside of clinical trials. Reason: lack of evidence for effectiveness and safety.
NICE — United Kingdom (2020). Two NICE evidence reviews (puberty blockers and cross-sex hormones) classified the evidence base as very low certainty. None of the studies identified met modern methodological standards.
COHERE — Finland (2020). The Finnish Council for Choices in Health Care revised its protocol: psychotherapy as first-line treatment, medical transition for minors only in exceptional cases and within a research setting.
UKOM — Norway (2023). The Norwegian UKOM classified transgender care for minors as experimental; existing protocols do not meet the requirements for evidence-based care.
WPATH Files (2024). Internal discussions among WPATH clinicians acknowledge that informed consent with minors is problematic and that serious side effects (bone density, fertility, cognitive development) are not adequately explained.